id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-0198-0008,FDA,FDA-2024-E-0198,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-09-19T04:00:00Z,2025,9,2025-09-19T04:00:00Z,,2025-09-19T17:51:55Z,,0,0,09000064b8fb006f
FDA-2024-E-0198-0007,FDA,FDA-2024-E-0198,Determination of Regulatory Review Period for Purposes of Patent Extension; SOHONOS,Notice,Determinations,2024-12-18T05:00:00Z,2024,12,2024-12-18T05:00:00Z,2025-02-19T04:59:59Z,2024-12-20T18:22:56Z,2024-29964,0,0,090000648687b925
FDA-2024-E-0198-0006,FDA,FDA-2024-E-0198,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-11-01T04:00:00Z,2024,11,2024-11-01T04:00:00Z,,2024-11-01T13:26:51Z,,0,0,09000064867ec9f2
FDA-2024-E-0198-0004,FDA,FDA-2024-E-0198,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-03-22T04:00:00Z,2024,3,2024-03-22T04:00:00Z,,2024-03-22T17:49:20Z,,0,0,090000648648cc14
FDA-2024-E-0198-0003,FDA,FDA-2024-E-0198,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-02-09T05:00:00Z,2024,2,2024-02-09T05:00:00Z,,2024-02-09T15:36:03Z,,0,0,09000064863f7a2f
FDA-2024-E-0198-0001,FDA,FDA-2024-E-0198,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-01-19T05:00:00Z,2024,1,2024-01-19T05:00:00Z,,2024-01-19T14:30:29Z,,0,0,0900006486391be6
FDA-2024-E-0198-0002,FDA,FDA-2024-E-0198,"Patent Extension Application from CLARK & ELBING LLP (on behalf of Ipsen Biopharmaceuticals, Inc.)",Other,Application,2024-01-19T05:00:00Z,2024,1,2024-01-19T05:00:00Z,,2024-01-19T14:32:42Z,,0,0,0900006486391bea
FDA-2024-E-0198-0005,FDA,FDA-2024-E-0198,Exhibit 1-10,Supporting & Related Material,Background Material,2024-01-19T05:00:00Z,2024,1,,,2024-09-18T18:43:51Z,,0,0,090000648639210e